Stocks · News reference
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 24, 2026, 6:50 PM
- Checked
- Jun 24, 2026, 6:55 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading